signal management

Including signal detection, validation, prioritization, and assessment

Two men reviewing data on computer screen Two men reviewing data on computer screen

Signal Management Services

ProPharma has deep expertise across all signal detection and management activities, including validation, prioritization, and assessment using data from a wide range of sources that are relevant for signal detection for the individual product(s). We are also fully trained and experienced in the EudraVigilance Data Analysis System (EVDAS) functionality and can support MAHs to comply with their obligations for signal detection and management. We leverage our robust knowledge to select the most efficient and effective method(s) for each product that is compliant with legislative requirements.

ProPharma's simple but scalable model of signal detection and management allows clients to obtain the exact services necessary throughout the entire life cycle of their products.

Signal management is a critical process for the proactive and timely identification of potential new safety risks for medicinal products that require the utmost expertise. Signal management can be deployed throughout both the clinical development and post-marketing phases of the product lifecycle. Safety issues may affect the benefit-risk balance of the product, requiring updates to product labels and other steps that help protect patients from harm.

Signal Detection in Pharmacovigilance

Signal detection in pharmacovigilance is the systematic process of identifying and evaluating potential safety signals in the data relating to a pharmaceutical product. This process involves scrutinizing various data sources for previously unrecognized adverse events or changes in patterns of known adverse events, which might be caused by a medicine. This is vital to monitor and assure the safety of a pharmaceutical product throughout its life cycle.

Key Steps in Signal Management

  • Signal Detection: Identifying potential safety signals using various data sources such as adverse event databases, literature, and other data.

  • Signal Validation: Verifying the identified signals to ensure they are genuine and warrant further investigation.

  • Signal Confirmation: Ensuring that the identified signal is supported by robust, scientific evidence.

  • Signal Assessment: Analyzing the available data to evaluate the relationship between the medicinal product and the observed risk and providing recommendations for mitigating risk to patient safety.

  • Communication: Working with the Client to inform regulatory authorities, healthcare professionals, patients, and the public about the findings and any new safety measures or recommendations resulting from signals in the management procedure.

  • Documentation: Recording all activities, assessments, decisions, and communications for accountability and future reference.

Significance of Signal Management

Man reviewing data on a computer montior
  • Patient Safety: Ensures that any potential safety concerns with pharmaceutical products are identified and managed to safeguard patients.

  • Regulatory Compliance: Ensures that regulatory requirements for monitoring and ensuring product safety are met.

  • Informed Decision Making: Helps healthcare professionals and patients make informed decisions about medicinal products.

  • Risk-Benefit Balance: Ensures that the benefits of a pharmaceutical product continue to outweigh its risks during the entire lifecycle.

How ProPharma Overcomes Signal Management Challenges

 

  • Data Quality: Defining robust strategies to analyze available data.

  • Timely Decision Making: Ensuring that decisions and communications are made in a timely manner to protect public health.

  • Global Consistency: Globally harmonized processes to collect, process, and assess data.

Two healthcare professionals talking at a table

News & Insights

WHO Issues Guidance on Antibiotic Pollution Control

December 19, 2024

WHO Issues Guidance on Antibiotic Pollution Control

WHO issues guidance to control antibiotic pollution from manufacturing, addressing environmental and global health impacts of antimicrobial resistance.

Nonclinical Drug Development: FDA Recommendations for Confirming an Ames Positive Finding

December 18, 2024

Nonclinical Drug Development: FDA Recommendations for Confirming an Ames Positive Finding

Explore FDA's recommendations on follow-up testing for Ames-positive drugs to support first-in-human clinical trials. Learn how to navigate FDA regulations and ensuring successful product development.

Navigating Market Access & Reimbursement Strategy for Medical Devices in Europe

December 17, 2024

Navigating Market Access & Reimbursement Strategy for Medical Devices in Europe

Explore the importance of market access and reimbursement strategies for medical devices and in vitro diagnostics (IVDs) in Europe. Learn how early planning and the new European HTAR can enhance the...

ProPharma Appoints Brian Tuttle as Chief Financial Officer

October 21, 2024

ProPharma Appoints Brian Tuttle as Chief Financial Officer

ProPharma appoints Brian Tuttle as CFO to drive financial strategy and accelerate global growth, leveraging his 20 years of life sciences industry experience.

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Names Dawn Sherman Chief Executive Officer

September 30, 2024

ProPharma Names Dawn Sherman Chief Executive Officer

Dawn Sherman rejoins ProPharma as CEO, bringing nearly 30 years of industry experience to lead the regulatory, clinical, and compliance services provider.

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

ProPharma Receives 2024 CRO Leadership Award

June 13, 2024

ProPharma Receives 2024 CRO Leadership Award

ProPharma wins 2024 CRO Leadership Award for exceeding expectations in key categories, solidifying its position as a top global research consulting organization in the life sciences industry.

Infographic The Cost of Poor Project Management - ProPharma

June 10, 2022

The Cost of Poor Project Management

Project Management isn’t for the faint of heart. There is a shockingly high rate of project failure… but on the other hand, great project management can be a key differentiator that leads a company...

Infographic Successfully Passing MHRA Inspections for Overseas Manufacturing Sites - ProPharma

August 31, 2022

Successfully Passing MHRA Inspections for Overseas Manufacturing Sites

ProPharma offers GMP and GDP compliance services from clinical development to commercial distribution of the products' lifecycle. ProPharma’s Compliance and Quality team completed the first on-site...

Infographic Navigating the Generic Drug Application and Approval Process - ProPharma

October 4, 2021

Navigating the Generic Drug Application and Approval Process

Navigating the generic drug application and approval process can be challenging. From pre-filing through post-approval, find out exactly what needs to be done for your Abbreviated New Drug...

News & Insights

ProPharma Appoints Brian Tuttle as Chief Financial Officer

October 21, 2024

ProPharma Appoints Brian Tuttle as Chief Financial Officer

ProPharma appoints Brian Tuttle as CFO to drive financial strategy and accelerate global growth, leveraging his 20 years of life sciences industry experience.

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Names Dawn Sherman Chief Executive Officer

September 30, 2024

ProPharma Names Dawn Sherman Chief Executive Officer

Dawn Sherman rejoins ProPharma as CEO, bringing nearly 30 years of industry experience to lead the regulatory, clinical, and compliance services provider.

Previous Post Arrow Next Post Arrow
ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

ProPharma Receives 2024 CRO Leadership Award

June 13, 2024

ProPharma Receives 2024 CRO Leadership Award

ProPharma wins 2024 CRO Leadership Award for exceeding expectations in key categories, solidifying its position as a top global research consulting organization in the life sciences industry.

Previous Award Arrow Next Award Arrow
WHO Issues Guidance on Antibiotic Pollution Control

December 19, 2024

WHO Issues Guidance on Antibiotic Pollution Control

WHO issues guidance to control antibiotic pollution from manufacturing, addressing environmental and global health impacts of antimicrobial resistance.

Nonclinical Drug Development: FDA Recommendations for Confirming an Ames Positive Finding

December 18, 2024

Nonclinical Drug Development: FDA Recommendations for Confirming an Ames Positive Finding

Explore FDA's recommendations on follow-up testing for Ames-positive drugs to support first-in-human clinical trials. Learn how to navigate FDA regulations and ensuring successful product development.

Navigating Market Access & Reimbursement Strategy for Medical Devices in Europe

December 17, 2024

Navigating Market Access & Reimbursement Strategy for Medical Devices in Europe

Explore the importance of market access and reimbursement strategies for medical devices and in vitro diagnostics (IVDs) in Europe. Learn how early planning and the new European HTAR can enhance the...

Previous Post Arrow Next Post Arrow
Infographic The Cost of Poor Project Management - ProPharma

June 10, 2022

The Cost of Poor Project Management

Project Management isn’t for the faint of heart. There is a shockingly high rate of project failure… but on the other hand, great project management can be a key differentiator that leads a company...

Infographic Successfully Passing MHRA Inspections for Overseas Manufacturing Sites - ProPharma

August 31, 2022

Successfully Passing MHRA Inspections for Overseas Manufacturing Sites

ProPharma offers GMP and GDP compliance services from clinical development to commercial distribution of the products' lifecycle. ProPharma’s Compliance and Quality team completed the first on-site...

Infographic Navigating the Generic Drug Application and Approval Process - ProPharma

October 4, 2021

Navigating the Generic Drug Application and Approval Process

Navigating the generic drug application and approval process can be challenging. From pre-filing through post-approval, find out exactly what needs to be done for your Abbreviated New Drug...

Previous Resource Arrow Next Resource Arrow